中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:567 更新时间:2025-12-14
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!将品牌入驻外推网,定制中生北控BioSino品牌推广信息,可以显著提高中生北控BioSino产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

三部门:加强商务和金融协同,更大力度提振消费

36氪获悉,商务部办公厅、中国人民银行办公厅、金融监管总局办公厅发布关于加强商务和金融协同,更大力度提振消费的通知。其中提出,加大消费重点领域金融支持。加强大宗耐用消费品、数码产品等消费金融服务,挖掘商品消费升级潜能。推动金融机构与平台、重点商户合作,走进商超卖场,完善分期付款、信用卡、手机银行、数字人民币等产品服务模式,更好满足消费者换新需求。根据客户还款能力和信用情况,合理确定贷款发放比例、期限和利率,落实好个人消费贷款额度、期限、利率差异化政策,加快推动个人消费贷款业务发展。适当减免汽车以旧换新过程中提前结清贷款产生的违约金。加强金融机构与内外贸一体化重点企业和平台对接,提供境内外交易撮合服务,完善跨境供应链融资模式,支持更多企业内外贸一体化经营,扩大内贸险承保规模,支持更多优质外贸产品进入国内市场。

50分钟前

防止 AI 人才外流,OpenAI 调整薪酬政策

12月14日,据《华尔街日报》报道,OpenAI 在刚刚过去的一周告诉员工,该公司将取消一项薪酬政策。该政策规定员工在公司工作至少六个月后才能获得股权归属。这六个月就是所谓的“归属悬崖”。如果 OpenAI 员工在六个月内离职,任何股票都拿不到。(IT之家)

50分钟前

长裕集团主板IPO12月19日上会

根据安排,长裕控股集团股份有限公司(以下简称“长裕集团”)主板IPO将于12月19日上会迎考。据了解,长裕集团主要从事锆类产品、特种尼龙产品、精细化工产品的研发、生产和销售,公司IPO于2025年5月21日获得上交所受理,当年6月13日进入问询阶段。本次冲击上市,长裕集团拟募集资金约7亿元,扣除发行费用后,将投资于4.5万吨超纯氧氯化锆及深加工项目、年产1万吨高性能尼龙弹性体制品项目、年产1000吨生物陶瓷及功能陶瓷制品项目。(北京商报) 分享到

50分钟前

凌钢与上海钢联签署战略合作协议

近日,凌钢与上海钢联电子商务股份有限公司签署战略合作协议。根据协议,双方将聚焦三大核心方向:一是依托上海钢联数据优势,助力凌钢优特钢等拳头产品拓展市场;二是共建价格监测、供需分析等数字化服务体系,赋能凌钢生产经营决策;三是探索产业链延伸开拓等创新合作模式,通过数字赋能构建“采、产、销”一体化生态。(人民财讯)

50分钟前

《疯狂动物城2》总票房破35亿

据猫眼专业版数据,电影《疯狂动物城2》上映19天,总票房破35亿​​。

50分钟前

本页详细列出关于中生北控BioSino的品牌信息,含品牌所属公司介绍,中生北控BioSino所处行业的品牌地位及优势。
咨询